| Secondary |
| Product Used For Unknown Indication |
63.8% |
| Attention Deficit/hyperactivity Disorder |
5.2% |
| Multiple Sclerosis Relapse |
5.2% |
| Chemotherapy |
3.4% |
| Depression |
3.4% |
| Hypertension |
3.4% |
| Prophylaxis |
3.4% |
| Anxiety |
1.7% |
| Blood Potassium Decreased |
1.7% |
| Eye Pruritus |
1.7% |
| Juvenile Idiopathic Arthritis |
1.7% |
| Multiple Sclerosis |
1.7% |
| Muscle Spasms |
1.7% |
| Pain In Extremity |
1.7% |
|
| Suicide Attempt |
22.2% |
| Urinary Tract Infection |
22.2% |
| Rash Pruritic |
11.1% |
| Tremor |
11.1% |
| Urinary Tract Infection Staphylococcal |
11.1% |
| Vascular Complication Associated With Device |
11.1% |
| Weight Increased |
11.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
58.3% |
| Multiple Sclerosis |
7.3% |
| Pain |
6.2% |
| Premedication |
6.2% |
| Back Pain |
2.1% |
| Osteoporosis |
2.1% |
| Rheumatoid Arthritis |
2.1% |
| Hepatitis C |
1.9% |
| Depression |
1.5% |
| Headache |
1.5% |
| Arthritis |
1.3% |
| Psoriatic Arthropathy |
1.3% |
| Relapsing-remitting Multiple Sclerosis |
1.3% |
| Anxiety |
1.1% |
| Coronary Artery Disease |
1.1% |
| Diabetes Mellitus |
1.1% |
| Non-small Cell Lung Cancer |
1.1% |
| Aggression |
0.9% |
| Hypothyroidism |
0.9% |
| Incontinence |
0.9% |
|
| Drug Ineffective |
9.7% |
| Weight Increased |
9.7% |
| Weight Decreased |
8.1% |
| Pain In Extremity |
6.5% |
| Vomiting |
6.5% |
| Intervertebral Disc Protrusion |
4.8% |
| Nausea |
4.8% |
| Pain |
4.8% |
| Paraesthesia |
4.8% |
| Swelling |
4.8% |
| Therapeutic Response Decreased |
4.8% |
| White Blood Cell Count Decreased |
4.8% |
| Breast Cancer |
3.2% |
| Injection Site Bruising |
3.2% |
| Injection Site Erythema |
3.2% |
| Injection Site Reaction |
3.2% |
| Injection Site Swelling |
3.2% |
| Malignant Neoplasm Progression |
3.2% |
| Multiple Sclerosis Relapse |
3.2% |
| Nasopharyngitis |
3.2% |
|
| Interacting |
| Depression |
50.0% |
| Migraine |
50.0% |
|
| Platelet Function Test Abnormal |
100.0% |
|
